News Image

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Provided By GlobeNewswire

Last update: Apr 1, 2025

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema.

Read more at globenewswire.com

PHARVARIS NV

NASDAQ:PHVS (7/23/2025, 8:00:00 PM)

After market: 20.84 0 (0%)

20.84

-2.28 (-9.86%)



Find more stocks in the Stock Screener

Follow ChartMill for more